1. Home
  2. ODD vs CMPX Comparison

ODD vs CMPX Comparison

Compare ODD & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ODD

ODDITY Tech Ltd.

HOLD

Current Price

$12.39

Market Cap

688.4M

Sector

N/A

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$2.06

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ODD
CMPX
Founded
2018
2014
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
688.4M
927.5M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
ODD
CMPX
Price
$12.39
$2.06
Analyst Decision
Hold
Strong Buy
Analyst Count
11
9
Target Price
$41.00
$14.57
AVG Volume (30 Days)
1.3M
12.1M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$22.92
$934.41
P/E Ratio
$16.73
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.80
$1.61
52 Week High
$79.18
$6.88

Technical Indicators

Market Signals
Indicator
ODD
CMPX
Relative Strength Index (RSI) 35.09 34.36
Support Level $10.80 $1.61
Resistance Level $16.04 $3.54
Average True Range (ATR) 0.87 0.14
MACD -0.13 0.13
Stochastic Oscillator 15.87 78.75

Price Performance

Historical Comparison
ODD
CMPX

About ODD ODDITY Tech Ltd.

ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage. Geographically, the company generates majority revenue from United states followed by other countries and Israel.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: